Skip To Main Content
Tine Juul Monberg on Muck Rack

Tine Juul Monberg

As seen in: medRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tine Juul

Contact Tine Juul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and feasibility of blood-derived Multiple Antigen-Specific Endogenous T cells (MASE-T) for metastatic melanoma

|
By Marcus Svensson Frej, Cecilie Lund Vestergaard, Tine Juul Monberg, Siri Amanda Tvingsholm
| medRxiv
TJM, SAT, MSF, CV, MO, JWK, RBH, NJ, JSG, SKL and OM declares no competing interests. THB has received personal payment for lectures/presentation from Bristol Myers Squibb. ARC is co-founder of PokeAcell, developer of the Ag-scaffold technology and has stokcs or stock options in PokeAcell and Cymab. SRH is co-inventor of two patents related to the Ag-scaffold technology (EP 16205918.2 and 18178769.8) filled and owned by the Technical University of Denmark.
Open in Who Shared Issue with article?
See all 1 articles